77 related articles for article (PubMed ID: 38669390)
1. Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
Liu M; Zhao Z; Wang C; Sang S; Cui Y; Lv C; Yang X; Zhang N; Xiong K; Chen B; Dong Q; Liu K; Gu Y
Cancer Lett; 2024 Jul; 594():216991. PubMed ID: 38797232
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract][Full Text] [Related]
3. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges.
Maleki Vareki S; Davar D
Nat Rev Clin Oncol; 2024 Jun; 21(6):405-406. PubMed ID: 38509333
[No Abstract] [Full Text] [Related]
4. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
6. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
8. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
9. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
10. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
11. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
12. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of
Li Z; Wang X; Yang Y; Shi F; Zhang W; Wang Q; Wang S
Cells; 2022 Nov; 11(23):. PubMed ID: 36497098
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H; Liu J; Zhu S; Miao K; Li Z; Qi X; Huang L; Guo L; Wang Y; Cai Y; Lin Y
Front Oncol; 2022; 12():945843. PubMed ID: 36185247
[TBL] [Abstract][Full Text] [Related]
15.
Zhang W; Lin Z; Shi F; Wang Q; Kong Y; Ren Y; Lyu J; Sheng C; Li Y; Qin H; Wang S; Wang Q
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884556
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]